Business Wire28d
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
The poster presentation titled, Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of ...
Cure Today25d
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...